Banner - Cardiologist
IDA and heart failure* 17% of chronic heart failure (HF) patients had IDA according to a 2011 prospective study of 157 patients with chronic HF.24
IDA and heart failure* 17% of chronic heart failure (HF) patients had IDA
according to a 2011 prospective study of 157 patients with chronic HF.24
*Based on a prospective assessment of clinical and iron indexes in 157 consecutively eligible patients with chronic heart failure at dedicated heart failure clinics at 2 UK hospitals and 22 control subjects with no known medical problems or regular medications. Chronic heart failure was defined based on a >6-month history of appropriate symptoms and signs and a left ventricular ejection fraction ≤45%. Anemia was defined as Hb ≤13 g/dL in men and <12 g/dL in women, and iron deficiency was principally defined as TSAT <20%.
IDA is a risk for cardiology patients
IDA is a risk for
IDA is a comorbidity for many chronic HF patients.25 Patients with chronic HF can suffer from gastrointestinal bleeding, malabsorption, and inflammation, which all can aid in causing iron deficiency or iron deficiency anemia.26,27 IDA can have detrimental effects in patients with coronary artery disease, HF, and pulmonary hypertension, and possibly in patients undergoing cardiac surgery.28
The incidence of IDA was greater among patients with more severe New York Heart Association (NYHA) functional class 25†
†The effects of changes in iron, anemia, or NYHA functional class status over time should not be inferred.
‡Patients with both iron deficiency and anemia were older and had a higher NYHA class, more comorbidities, and higher biomarker levels compared with those with no iron deficiency and no anemia.
Diagnosing and managing IDA
Three of the most common tests used to diagnose IDA are hemoglobin (Hb), ferritin, and transferrin saturation (TSAT).See the common laboratory markers used to monitor IDA.
Injectafer restores iron
Injectafer is a dextran-free IV iron indicated for adult IDA patients of various etiologies, and is the only IV iron that delivers up to 1500 mg of iron in just 2 administrations, separated by at least 7 days.
§For adult patients weighing less than 50 kg (110 lb), give each dose as 15 mg/kg body weight for a total cumulative dose not to exceed 1500 mg of iron per course of treatment.
||When administered via IV infusion, dilute up to 750 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not <2 mg of iron per mL and administer over at least 15 minutes. When administered as a slow IV push, give at the rate of approximately 100 mg (2 mL) per minute.
Injectafer is not indicated to treat the symptoms of IDA.
Gradient Bar links- Choosing Injectafer
Important Safety Information
Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.
IMPORTANT SAFETY INFORMATION
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).
The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.
To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.